Bio-Techne TECH

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Bio-Techne (TECH) Business Model and Operations Summary
    Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

    Key Insights

    Bio-Techne (TECH) Core Market Data and Business Metrics
    • Latest Closing Price

      $54.63
    • Market Cap

      $7.73 Billion
    • Average Daily Volume

      2,372,990 Shares
    • 52-Week Range

      $46.01-$83.62
    • Price-Earnings Ratio

      118.76
    • Total Outstanding Shares

      156.77 Million Shares
    • CEO

      Mr. Kim Kelderman
    • Total Employees

      3,100
    • Current Dividend

      $0.08 Per Share Quarterly
    • IPO Date

      May 8, 1989
    • SIC Description

      Biological Products, (no Disgnostic Substances)
    • Headquarters

      614 Mckinley Pl N E, Minneapolis, MN, 55413

    Earnings Reports

    Expected vs. Actual Quarterly Earnings-Per-Share & Revenue

    Short Volume

    Daily short volume activity identifies short-term trading pressure and potential price volatility

    Short Interest

    Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential

    Revenue Breakdown

    Distribution of revenue across unique business segments & geographies

    Cash Flow Statement

    July 1, 2024 to June 30, 2025

    Income Statement

    July 1, 2024 to June 30, 2025

    Comprehensive Income

    July 1, 2024 to June 30, 2025

    Balance Sheet

    July 1, 2024 to June 30, 2025

    Historical Stock Splits

    If you bought 1 share of TECH before November 30, 2022, you'd have 4 shares today

    Historical Dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about TECH from trusted financial sources

    Related Companies

    Publicly traded companies similar to Bio-Techne (TECH)
    Boost your savings and earn 3.95% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.